Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Kangstem Biotech Realizes Global Big Pharma and Organoid Cooperation Plan... "Proposal for Evaluation of Efficacy of New Drugs for Skin Disease"
24
2025.07
Kangstem Biotech recently held a partnering meeting with multinational pharmaceutical companies in the United States and Europe, including Big Pharma, and said it will promote specific business cooperation with global pharmaceutical companies, including evaluating the efficacy of new drugs.
Kangstem Biotech recently held a partnering meeting with multinational pharmaceutical companies in the United States and Europe, including Big Pharma, and said it will promote specific business cooperation with global pharmaceutical companies, including evaluating the efficacy of new drugs.
The company discussed with global big pharmas about skin and hair follicle organoids, evaluating skin disease models, and visiting research institutes. Using the company's skin organoid disease platform, we are discussing joint experiments such as genetic analysis and effectiveness evaluation to receive private new drug substances being developed by global pharmaceutical companies. A large American pharmaceutical company plans to visit Kangstem Biotech to directly identify hair follicle organoids and discuss specific partnering plans.
Kangstem Biotech, head of the business development division, said, "Global pharmaceutical companies' interest in skin organoids is very high. Kangstem Biotech's skin organoid technology is globally unique, said the general manager of technology introduction under Big Mapa, which is discussing joint experiments with the company. We have already provided the results of preliminary experiments on atopic treatment-related antibody drugs. Through this evaluation, we can launch an efficacy evaluation platform using skin organoids and expect to receive a lot of attention from CROs for efficacy evaluation, including multinational pharmaceutical companies, he said.
Based on this consultation, Kangstem Biotech plans to implement various and rapid strategies to achieve global business results by the end of this year, such as establishing preemptive partnerships with multinational pharmaceutical companies such as the U.S. and Europe and reviewing phased technology transfer based on organoid R&D results.
For more details, please refer to the link below